Max Robotics — Global Service Robot Directory + US Certification

About

Tohru Yoneyama is a leading urologic oncologist whose research bridges geriatric oncology and surgical innovation, with a particular focus on prostate and bladder cancers. His most influential work centers on frailty assessment in elderly cancer patients, where he pioneered the use of the Geriatric 8 (G8) screening tool to guide treatment decisions. His landmark 2020 study evaluating G8 in 540 prostate cancer patients (40 citations) demonstrated how frailty screening can predict surgical outcomes and treatment tolerability. Yoneyama’s FRART-PC and FRAP studies further established frailty as a critical predictor of postoperative pain and surgical contraindication, while his longitudinal FRARP-QL study showed its impact on quality of life after robot-assisted radical prostatectomy. Beyond frailty, he has investigated cell-free DNA as a biomarker for surgical damage and compared oncologic outcomes between robotic and open cystectomy for muscle-invasive bladder cancer, including a recent multicenter study on peritoneal carcinomatosis. With over 130 cumulative citations across his most-cited works, Yoneyama’s research has fundamentally shaped how urologists approach surgical decision-making in older, frail patients, advancing personalized care in urologic oncology.